Min Kyounghee, Yenilmez Batuhan, Kelly Mark, Echeverria Dimas, Elleby Michael, Lifshitz Lawrence M, Raymond Naideline, Tsagkaraki Emmanouela, Harney Shauna M, DiMarzio Chloe, Wang Hui, McHugh Nicholas, Bramato Brianna, Morrision Brett, Rothstein Jeffery D, Khvorova Anastasia, Czech Michael P
Program in Molecular Medicine, University of Massachusetts Chan Medical School, USA.
RNA Therapeutics Institute, University of Massachusetts Chan Medical School, USA.
bioRxiv. 2023 Oct 19:2023.05.03.539244. doi: 10.1101/2023.05.03.539244.
Circulating lactate is a fuel source for liver metabolism but may exacerbate metabolic diseases such as nonalcoholic steatohepatitis (NASH). Indeed, haploinsufficiency of lactate transporter monocarboxylate transporter 1 (MCT1) in mice reportedly promotes resistance to hepatic steatosis and inflammation. Here, we used adeno-associated virus (AAV) vectors to deliver thyroxin binding globulin (TBG)-Cre or lecithin-retinol acyltransferase (Lrat)-Cre to MCT1 mice on a choline deficient, high fat NASH diet to deplete hepatocyte or stellate cell MCT1, respectively. Stellate cell MCT1KO (AAV-Lrat-Cre) attenuated liver type 1 collagen protein expression and caused a downward trend in trichrome staining. MCT1 depletion in cultured human LX2 stellate cells also diminished collagen 1 protein expression. Tetra-ethylenglycol-cholesterol (Chol)-conjugated siRNAs, which enter all hepatic cell types, and hepatocyte-selective tri-N-acetyl galactosamine (GN)-conjugated siRNAs were then used to evaluate MCT1 function in a genetically obese NASH mouse model. MCT1 silencing by Chol-siRNA decreased liver collagen 1 levels, while hepatocyte-selective MCT1 depletion by AAV-TBG-Cre or by GN-siRNA unexpectedly increased collagen 1 and total fibrosis without effect on triglyceride accumulation. These findings demonstrate that stellate cell lactate transporter MCT1 significantly contributes to liver fibrosis through increased collagen 1 protein expression and , while hepatocyte MCT1 appears not to be an attractive therapeutic target for NASH.
循环中的乳酸是肝脏代谢的燃料来源,但可能会加剧非酒精性脂肪性肝炎(NASH)等代谢性疾病。事实上,据报道小鼠中乳酸转运体单羧酸转运体1(MCT1)的单倍剂量不足可促进对肝脂肪变性和炎症的抵抗。在这里,我们使用腺相关病毒(AAV)载体将甲状腺素结合球蛋白(TBG)-Cre或卵磷脂-视黄醇酰基转移酶(Lrat)-Cre分别递送至胆碱缺乏、高脂肪NASH饮食的MCT1小鼠,以分别耗尽肝细胞或星状细胞中的MCT1。星状细胞MCT1基因敲除(AAV-Lrat-Cre)减弱了肝脏I型胶原蛋白的表达,并导致三色染色呈下降趋势。在培养的人LX2星状细胞中耗尽MCT1也会减少胶原蛋白1的表达。然后使用能进入所有肝细胞类型的四乙二醇-胆固醇(Chol)偶联的小干扰RNA(siRNA)和肝细胞选择性的三-N-乙酰半乳糖胺(GN)偶联的siRNA,来评估基因肥胖NASH小鼠模型中MCT1的功能。Chol-siRNA沉默MCT1可降低肝脏胶原蛋白1水平,而通过AAV-TBG-Cre或GN-siRNA对肝细胞进行选择性MCT1耗尽,出乎意料地增加了胶原蛋白1和总纤维化程度,而对甘油三酯积累没有影响。这些发现表明,星状细胞乳酸转运体MCT1通过增加胶原蛋白1的表达,对肝纤维化有显著贡献,而肝细胞MCT1似乎不是NASH的一个有吸引力的治疗靶点。